Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601165 | 0.80 | RAB9A (0.54) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL27961408 | 0.78 | HCAR3 (0.45) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL23258237 | 0.76 | EPHX2 (0.49) | EPHX2RAB9ABRAFKDRMAPK14 | |
| SCHEMBL28729179 | 0.75 | EPHX2 (1.00) | EPHX2RAB9ANPC1NAMPTMEN1 | |
| SCHEMBL11003408 | 0.75 | EPHX2 (1.00) | EPHX2RAB9ANPC1NAMPTMEN1 | |
| SCHEMBL20642067 | 0.74 | FFAR1 (0.52) | EPHX2RAB9ANPC1KDRNAMPT | |
| SCHEMBL17604064 | 0.73 | CDK1 (0.61) | EPHX2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL5809373 | 0.72 | EPHX2 (0.85) | EPHX2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL4084235 | 0.72 | MAPT (0.75) | EPHX2RAB9ANPC1KDRMAPK14 | |
| SCHEMBL18049033 | 0.71 | MAPT (0.57) | EPHX2RAB9ANPC1KDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | EPHX2 2928/4885RAB9A 1457/4885NPC1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.